Denali Deal & F-star’s Innovative Asset Centric Business Model
Executive Summary
Jane Dancer, chief business officer at F-star – a Cambridge, UK-based biotech – chats to Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe partnering conference in Cologne, Germany.
You may also be interested in...
Denali Buyout Validates F-star’s Asset-Centric Model
Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.
F-star Option Deal With Merck On Bispecific IO Antibodies
'Asset-centric' bispecific antibody developer F-star has agreed an option deal for a package of immuno-oncology-focused antibodies with Merck of Germany.
Up Front Or Back End? Considering The Best Structure For Milestone Fees
PwC partner Dmitri Drone explained that a deal for an asset with high commercial expectations is best structured with more emphasis on pre-approval than post-approval payments. A post-approval focus on shared risk is more appropriate when an asset is licensed at an earlier stage of development.